Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06727981

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Sponsor: Qilu Hospital of Shandong University

View on ClinicalTrials.gov

Summary

This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes

Official title: Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line/Neoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

OBSERVATIONAL

Enrollment

500

Start Date

2022-01-15

Completion Date

2028-01-15

Last Updated

2024-12-11

Healthy Volunteers

No

Interventions

DRUG

ICI plus Chemothearpy

This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.

DRUG

Chemotherapy

This intervention involves the administration of standard chemotherapy alone.

Locations (1)

Qilu Hospital of Shandong University

Jinan, Shandong, China